FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
KYMR Financial Statements
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Total Revenue
7.39M
3.74M
25.65M
10.29M
Cost of Revenue
0
2M
1.9M
1.5M
Gross Profit
7.39M
1.74M
23.75M
8.79M
Operating Expenses
88.15M
75.86M
74.67M
61.69M
Research and Development
71.82M
60.41M
57.3M
48.82M
Selling, General & Administrative Expenses
16.33M
15.46M
17.37M
14.37M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
16.33M
15.46M
17.37M
14.37M
Other Expenses
0
0
0
-47.32M
Operating Income
-80.75M
-72.12M
-50.92M
-52.91M
Total Other Income/Expenses Net
10M
9.64M
8.86M
4.35M
Income Before Tax
-70.75M
-62.49M
-42.06M
-48.56M
Income Tax
0
0
0
39k
Net Income
-70.75M
-62.49M
-42.06M
-48.56M
Basic EPS
-0.88
-0.82
-0.58
-0.69
EPS Diluted
-0.88
-0.82
-0.58
-0.69
Basic Average Shares
79.99M
76.13M
73.06M
70.77M
Diluted Average Shares
79.99M
76.13M
73.06M
70.77M
EBITDA
-68.71M
-60.43M
-40.1M
-46.99M
Retained Earning Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Retained Earnings (Previous Year)
-683.86M
-621.37M
-579.31M
-530.75M
Net Income
-70.75M
-62.49M
-42.06M
-48.56M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-754.61M
-683.86M
-621.37M
-579.31M
Other Distributions
-70.75M
-62.49M
-42.06M
-48.56M
PPE Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Gross PPE
97.86M
99.31M
100.44M
98.67M
Annual Depreciation
1.99M
2M
1.9M
1.5M
Capital Expenditure
-936k
189k
-4.69M
-7.4M
Net PPE
96.81M
97.12M
103.23M
104.57M
Intangible and Goodwill Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
